# Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC

> **NCT04174781** · PHASE2 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 61 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** DEB-TACE

## Key facts

- **NCT ID:** NCT04174781
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-20
- **Primary completion:** 2022-07-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2022-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04174781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04174781, "Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04174781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*